

TIDES EUROPE

Oligonucleotide & Peptide Therapeutics

12-14 NOVEMBER, 2024
HAMBURG, GERMANY

Hamburg Congress Centre

The Industry's Leading Event in Europe to Accelerate Therapeutics to Market

Expedite your R&D, improve your
CMC efficiency, and build new partnerships

Register by 23 August to save £800! →

TIDSEuropeEvent.com

Europe's Flagship Meeting For Oligonucleotide And Peptide Science, Technology And Networking




600+
Industry Experts

Fast-track your products to the clinic and beyond by collaborating with leading pharma, biotechs, academia and solution providers from Europe, North America and Asia.



100+
Case Studies And New
Data Presentations

Apply best practices and lessons learned from industry leaders working across the entire spectrum from discovery to clinic to CMC to manufacturing.



85+
Leading Exhibitors

Connect with leading manufacturing, technology, and service providers to drive your promising therapeutic towards commercial success.

What's New This Year?

New Sessions:

Case Studies of Innovations and Efficiencies in Oligonucleotide CMC

Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs

Targeted Delivery of Oligonucleotides and Preclinical Progress

Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls

Leveraging mRNA as A Broad Therapeutic Platform: Oncology & Beyond

New Workshops:

Unlocking Insights: CMC, Quality & Regulatory - A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program

Synthesis and Characterization of Long sgRNA for CRISPR/Cas

8:30	Registration and Coffee
	Optional Pre-Conference Morning Workshops 09:00-12:00
9:00	<p>Workshop #1: Synthesis, CMC and Characterization of Long and Complex Oligonucleotides</p> <p>Workshop Moderators: Thomas Rupp, Owner and Principal, Thomas Rupp Consulting AG, Germany Chris Oswald, Owner & Principal, Coswald Consulting, USA</p> <p>Workshop Description: The workshop will give an overview of manufacturing processes and CMC strategies for long and complex oligonucleotides, like sgRNA or aptamers. It will emphasize the CMC development from early discovery phase throughout the clinical phases and spotlight on cleaning/carryover, process development, analytical development, raw materials selection and control, impurity characterization, analytical tools and setting of specifications. The workshop will be split into a manufacturing-focused part ranging from early process development to scale-up, and an analytical part addressing process-, and product-related impurity formation and their control. After the presentations the speakers will jointly chair a panel discussion on CMC aspects.</p> <p>Topics to be Discussed:</p> <ul style="list-style-type: none">• CMC activities for long and complex oligonucleotide therapeutics or theranostics• Raw material selection and control• Understanding and controlling process and product-related impurities• Analytical tools and their application <p>Who Should Attend? Anyone interested in CMC, Impurity Control Strategies, and in-house or outsourced manufacturing of oligonucleotide therapeutics during pre-clinical and clinical development of synthetic RNA Therapeutics or Theranostics. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management</p>

Optional Pre-Conference Morning Workshops | 09:00-12:00

9:00 **Workshop #2: Unlocking Insights: CMC, Quality & Regulatory - A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program**

9:00 Workshop Co-Moderators' Welcome and Opening Remarks

Judy Carmody, Ph.D., Founder and Principal Consultant, Carmody Quality Solutions, LLC, USA

Melanie Cerullo, Chief Quality & Regulatory Officer, RecBioPharm, USA

9:05 CMC Strategies to Accelerate Development Whilst Not Sacrificing Quality

Judy Carmody, Ph.D., Founder and Principal Consultant, Carmody Quality Solutions, LLC, USA

10:20 Networking Refreshment Break

10:45 A Case Study on Best Practices and Manufacturing Lessons Learned from Sequence to IND for a Gene Editing Program

Melanie Cerullo, Chief Quality & Regulatory Officer, RecBioPharm, USA

12:00 Close of Workshop



Topics to Be Discussed:

- Development and Manufacturing Considerations: We will spotlight the critical points along the road in plasmid DNA, drug substance, and drug product process and analytical development and GMP manufacturing
- Regulatory and Quality Assurance: We will address the regulatory hurdles and how to navigate in the early phase landscape while still ensuring patient safety and successful IND submission
- Stability – how much and timing
- Setting Specifications for starting materials (plasmids), mRNA, sgRNA and LNP-DP
- How much detail is needed in the IND
- Future Perspectives

Who Should Attend?

Anyone interested in CMC, Impurity Control Strategies, Manufacturing of oligonucleotide therapeutics and Quality Assurance during pre-clinical and clinical development of chemical RNA Therapeutics or Theranostics. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management, Business Development

Agenda | Tuesday 12, November 2024

	Optional Pre-Conference Morning Workshops 09:00-12:00	
9:00	Workshop #3: Peptide Therapeutics 2.0: Design and Properties of New and Improved Peptides Workshop Moderators: Bruce Morimoto, Ph.D., Vice President, Drug Development, Alto Neuroscience, USA Alastair Hay, Ph.D., Vice President, Peptides, Almac, United Kingdom Workshop Overview: Over the last 20 years, peptide therapeutics have evolved from simple to complex. Peptide modifications are very common including the incorporation of unnatural amino acids, conjugation, and cyclization. This workshop will consist of a collection of presentations with a focus on various peptide modification chemistries leading to improve metabolic and therapeutic properties with a focus on case studies as examples of these approaches and applications.	
	Luncheon Spotlight Presentations	
12:00	Spotlight Presentation 	Spotlight Presentation 
	Main Conference Keynote Session	
13:10	Chairperson's Remarks	
13:15	Discovery of RNA-modifying Ribozymes Claudia Höbartner, Ph.D., Professor of Organic Chemistry, University of Würzburg, Germany	

Agenda | Tuesday 12, November 2024

Main Conference | Keynote Session

13:45 **How Novo Nordisk is Expanding our Technology Platforms Via Strategic Internal and External Investments**
Karina Thorn, Ph.D., Corporate VP and Head of Research, Global Nucleic Acid Therapies (GNAT), Novo Nordisk, Denmark

14:15 **Designing the Once-Weekly and Oral GLP-1 Semaglutide**
Jesper Lau, Ph.D., Vice President, Digital Science & Innovation, Novo Nordisk A/S, Denmark

Networking Refreshment Break in Poster and Exhibit Hall

15:15 **Discovery of Zosurabalpin**
Patrizio Mattei, Ph.D., Expert Scientist, Medicinal Chemistry, F. Hoffmann-La Roche Ltd., Switzerland


16:00 **An Update on Lilly's siRNA & RNA Editing Portfolio**
Maire Fiona Jung, Ph.D., VP & CSO, RNA, Lilly Institute of Genetic Medicine, Eli Lilly and Company

16:30 **n-Lorem Foundation: A Dream of Hope and Treatment for Nano-rare Patients Being Realized**
Stanley Crooke, M.D., Ph.D., Founder and CEO, n-lorem Foundation, USA

17:00 **Networking Reception in Poster and Exhibit Hall**
Join fellow attendees, speakers, exhibitors, and poster presenters for a fun evening of scientific exchange and networking in the exhibit hall.

18:30 **Close of Day One**







Agenda | Wednesday 13, November 2024

7:30	Morning Spotlight Presentation		
	Spotlight Presentation  Experts in Solid Dosage Technology <small>A Division of Spraying Systems Co.</small>		
	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Oligonucleotide Preclinical and Clinical Updates	Case Studies of Innovations and Efficiencies in Oligonucleotide CMC	Trends in Peptide Discovery and Synthesis
8:00	Chairperson's Remarks Yogesh Sanghvi, Ph.D., President, Rasayan, Inc., USA	Chairwoman's Remarks Sonja Merkas, Ph.D., Founder, Livinovea, Switzerland	Chairman's Remarks Christian Becker, Ph.D., Professor and Head of the Institute of Biological Chemistry, University of Vienna, Austria
8:05	New Weapons Against Multidrug Resistant Bacterial Infections via an RNA Therapeutics Antibiotic Drug Discovery Platform Peter Nielsen, Ph.D. Professor and Head of Center for Peptide-Based Antibiotics, University of Copenhagen, Denmark	Scaling Up Solution Phase Oligo Manufacturing and Future Innovations Yannick Fillon, Ph.D., Head of Oligonucleotide Process Chemistry, Biogen, USA	Discovery and Development of Disulfide-constrained Peptides Christina I. Schroeder, Ph.D., Senior Fellow, Peptide Therapeutics, Genentech, USA
8:35	Using the L-stereoisomer RNA Aptamer NOX-A12 to Enhance Efficacy in Solid Tumors Aram Mangasarian, Ph.D., Chief Executive Officer, TME Pharma, Germany	Biocatalytic Approaches to Oligonucleotides Manufacturing, a CMC Perspective Filippo Sladojevich, Ph.D., Senior Principal Scientist, Hoffmann-La Roche, Switzerland	Development of Membrane-Permeable Cyclic Peptides Christian Heinis, Ph.D., Associate Professor, Institute of Chemical Sciences and Engineering, EPFL, Switzerland
9:05	Oligonucleotide IMT504, a Drug Candidate for Complex Regional Pain Syndrome. Preclinical and Phase-I Clinical Results Alejandro Montaner, Ph.D., CEO, Immunalgia Therapeutics, Argentina	Designing a Safe, Sustainable, and Efficient Drug Manufacturing Processes for Oligonucleotide Based Products Ashish Garg, Ph.D., Director, Drug Product Development, Bioproduct Research and Development, Eli Lilly and Company, USA	Targeting Membrane-bound Proteins Using Cell-based Biopanning of Cyclized CLIPS™ Peptides in Phage-displayed Libraries Sheena Ong, Scientist, Biosynth



Agenda | Wednesday 13, November 2024

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Oligonucleotide Preclinical and Clinical Updates	Case Studies of Innovations and Efficiencies in Oligonucleotide CMC	Trends in Peptide Discovery and Synthesis
9:35	Networking Refreshment Break in Poster and Exhibit Hall		
10:15	Antisense Oligonucleotides for Treatment of Cancer and Kidney Diseases Frank Jaschinski, Ph.D., Chief Scientific Officer, Secarna Pharmaceuticals, Germany	Plant Design and Manufacturing Challenges with Insights from Leqvio Letizia Volpe, Ph.D., Site MS&T Head Chemical Operations, Novartis, Switzerland	Development of HER-096 as a Disease Modifying Therapy for Parkinson's Disease Antti Vuolanto, Chief Executive Officer, Herantis Pharma plc, Finland
10:45	RNA Therapies in Heart Failure - An Update Thomas Thum, M.D., Ph.D., CSO, CMO and Founder, Cardior Pharmaceuticals, Germany	NMR Platform Methods for Content and Loop Structure of Oligonucleotides Joan Malmstrøm, Ph.D., Principal Scientist, CMC Analytical Support, Novo Nordisk A/S, Denmark	Development of GUBamy, A Clinical Stage Long-acting Amylin Analogue Formulated at Neutral pH, Using StreaMLine - A ML-driven Peptide Drug Discovery Platform Morten Lundh, Ph.D., Director, Drug Discovery Innovation, Gubra A/S, Denmark
11:15	Clinical Update on Rugonersen Erich Koller, Ph.D., Senior Principal Scientist, Roche Innovation Center Basel, Switzerland	Panel Discussion: Process Development & Manufacturing of Oligos Moderator: Sonja Merkas, Ph.D., Founder, Livinovea, Switzerland Panelists: Yannick Fillon, Ph.D., Head of Oligonucleotide Process Chemistry, Biogen, USA Filippo Sladojevich, Ph.D., Senior Principal Scientist, Hoffmann-La Roche, Switzerland Ashish Garg, Ph.D., Director, Drug Product Development, Bioproduct Research and Development, Eli Lilly and Company, USA Letizia Volpe, Ph.D., Site MS&T Head Chemical Operations, Novartis, Switzerland	Targeted Innate Immune Stimulators as Therapeutics Christian Becker, Ph.D., Professor and Head of the Institute of Biological Chemistry, University of Vienna, Austria


Agenda | Wednesday 13, November 2024

11:45	Transition to Spotlight Presentations		
11:50	Oligo Manufacturing Innovations – From Synthesis through Concentration Tom Krebstakies, Ph.D., Sales Manager - Europe & Asia, Asahi Kasei Bioprocess 	Spotlight Presentation 	Spotlight Presentation 
12:20	Networking Luncheon in Poster and Exhibit Hall		
	Spotlight Presentations		
13:25	The Latest Tools for the Characterization of mRNA and Oligonucleotide Biopharmaceuticals by CE and LC-MS Stephen Lock, Ph.D., Senior Market Development Manager, Biopharma, EMEA, SCIEX 	Spotlight Presentation 	Spotlight Presentation 
	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Oligonucleotide Chemistry, Mechanism, SAR and Pre-Clinical	Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs	Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls
13:55	Chairman's Remarks Troels Koch, Ph.D., Chief Technology Officer, MiNa Therapeutics, Denmark	Chairman's Remarks Daniel Waschke, Ph.D., Technical Regulatory Manager, F. Hoffmann-La Roche Ltd., Switzerland	Chairman's Remarks Riccardo Bernasconi, Ph.D., Director Business Development, Bachem, Switzerland


Agenda | Wednesday 13, November 2024

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Oligonucleotide Chemistry, Mechanism, SAR and Pre-Clinical	Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs	Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls
14:00	Developing RNA Editing As a New Class of Medicine: From Mechanism to Therapeutic Applications Gerard Platenburg, Ph.D., Chief Scientific Officer, ProQR Therapeutics, The Netherlands	An Update on EMA Regulatory Guidelines for Oligonucleotides René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical Biotechnology, BfArM, Federal Institute for Drugs and Medical Devices, Germany (Invited)	How to Develop a Close-to-commercial Manufacturing Process for Peptide Drug Substance Gajan Santhakumar, Ph.D., Associate Principal Scientist, Early Chemical Development, AstraZeneca, United Kingdom
14:30	Increasing ASO Stability with Chemical Modifications Erich Koller, Ph.D., Senior Principal Scientist, Roche Innovation Center Basel, Switzerland	How to Prepare for a Successful IND/IMPd When Developing Oligonucleotide Therapeutics Hagen Cramer, Ph.D., Chief Technology Officer, QurAlis, USA	Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand Olivier Ludemann-Hombourger, Ph.D., Director, Global Innovation and Technology, PolyPeptide, France
15:00	Fatty Acid Conjugation to Enable Oligonucleotide Delivery into the CNS Beatriz Llamusi, Ph.D., Chief Scientific Officer & Co Founder, Arthex Biotech S.L., Spain	General Post-approval Observations and Trends in Oligo Programs from a Regulatory Perspective Tracey Burr, Ph.D., Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals, USA	A Generalized PAT Approach for Fast Peptide Purification Process Development and Production Control in CMC Settings Jörg Kittelmann, Ph.D., Principal Scientist, CMC Downstream API Development, Novo Nordisk, Denmark
15:30	<div>  Networking Refreshment Break in Poster and Exhibit Hall </div> <div> Afternoon Beer Sponsor  </div>		
16:15	AIC468 – A Novel Antisense Oligonucleotide in Clinical Development for Treatment of BKV Infections Holger Zimmermann, Ph.D., Chief Research and Development Officer, AiCuris Anti-infective Cures AG, Germany Eric van der Veer, Ph.D., Chief Innovation Officer, Hybridize Therapeutics, The Netherlands	Regulatory CMC Insights on Post-approval Changes for a siRNA Oligonucleotide Daniela Fischer, Ph.D., Associate Director Regulatory Affairs CMC, Novartis Pharmaceutical Manufacturing, Switzerland	Bachem CMC Presentation Bachem Speaker TBA







Agenda | Wednesday 13, November 2024

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Oligonucleotide Chemistry, Mechanism, SAR and Pre-Clinical	Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs	Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls
16:45	State of the Art siRNA – Delivery and Chemistry Tomaz Einfalt, Principal Investigator II xRNA, Novartis Institutes for BioMedical Research, Switzerland	Enzymatic Ligation, Regulatory Challenges and Potential Platform Approaches Sergey Tsukanov, Ph.D., Senior Director - Oligonucleotides, Synthetic Molecule Design & Development, Eli Lilly and Company, USA	Improving Efficiencies in Peptide API Process Development Yi Yang, Ph.D., Principal Scientist, Ferring Pharmaceuticals A/S, Denmark
17:15	 Evening Networking Reception in Hamburg This evening's networking reception will take place in a venue close to the TIDES Europe conference center. Join fellow attendees and speakers for drinks and small bites for a fun start to your evening out in Hamburg.		
19:00	Close of Day Two		

Agenda | Thursday 14, November 2024

7:30	Morning Spotlight Presentation		
	Enhancing the Activity and Delivery of Oligonucleotide Therapeutics with Modified Phosphoramidites and Nucleotides Xavier Gerard, Ph.D., Field Application Scientist, EMEA, Nucleic Acid Therapeutics (NATx) Division, Thermo Fisher Scientific, Switzerland 		
	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Leveraging Advances in mRNA and Genome Editing	Advances in Oligonucleotide Analytics and Characterization	Innovations in Peptide Discovery, Design and Peptide CMC
8:00	Chairperson's Remarks Christoph Kroener, Ph.D., Senior Director CMC IVAC Portfolio, BioNTech AG, Germany	Chairperson's Remarks Mike Webb, Ph.D., Founder and CEO, Mike Webb Pharma	Chairman's Remarks
8:05	Individualized Cancer Treatment Using mRNA Technology Christoph Kroener, Ph.D., Senior Director CMC IVAC Portfolio, BioNTech AG, Germany	From LC-UV to MS-based Methodology for the Analysis of siRNA Anthony Ehkirch, Ph.D., Principal Scientist and Analytical Expert, Novartis, Switzerland	Macrocyclic Peptides as Scaffolds in Drug Design David Craik, Ph.D., Professor of Biomolecular Structure, Institute for Molecular Bioscience, University of Queensland, Australia
8:35	Building a Platform Suitable for mRNA Therapeutics George Thom, Director, mRNA Team Leader, AstraZeneca, United Kingdom	Unlocking Guide RNA Quality: The Power of NGS Analysis Barbara Pfaff, Ph.D., QC Manager Molecular Sequencing, BioSpring GmbH, Germany	Switching off Transcription Factors Using Intracellular Library-derived Peptides Jody Mason, Ph.D., Professor of Biochemistry, University of Bath, United Kingdom

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Leveraging Advances in mRNA and Genome Editing	Advances in Oligonucleotide Analytics and Characterization	Innovations in Peptide Discovery, Design and Peptide CMC
9:05	Next Generation Lipid Nanoparticles for mRNA delivery Vusala Ibrahimova, Ph.D., Research Scientist, CureVac SE, Germany	Optimization of the Solid-phase Oligonucleotide Detritylation Reaction Using In-line IR PAT Steven Stanton, Senior Scientist, Oligonucleotide Process Chemistry, AstraZeneca, United Kingdom	Development of DMF-free SPPS Processes Trine Puggaard Petersen, Ph.D., Senior, Development Scientist, Novo Nordisk, Denmark
9:35	Networking Refreshment Break in Poster and Exhibit Hall		
10:15	In vivo Genome Editing: Translating Science from Bench to Bedside Zi Jun Emma Wang, Ph.D., Chief Technology Officer, YolTech Therapeutics, China	Characterization of siRNA Product-related Impurities by HILIC Lucas Bethge, Ph.D., VP, Group Leader Oligonucleotide Chemistry, Silence Therapeutics, Germany	Flow SPPS – Towards Greener and More Efficient Peptide Manufacturing Eike-Fabian Sachs, Head of Development Frankfurt, CordenPharma International GmbH, Germany
10:45	Enhancing CRISPR/Cas9 Gene Editing in Lung Tumor Cells: Optimization of Lipid Nanoparticles for Potential Inhalation Therapy Simone Carneiro, Ph.D., Postdoctoral Fellow, LMU Munich, Germany	The Role of Digital Data Analytics (DDA) in Escalating GSK's Bepiroversin Analytical Development Procedures Marah Faron, Digital Innovation Lead, GSK, United Kingdom	Get Rid of Side Reactions on Cys and Met Residues During SPPS and Cleavage Beatriz de la Torre, Ph.D., Research Professor, Laboratory of Medicine and Medical Sciences, University of KwaZulu- Natal, South Africa
11:15	Delivery of Genomic Medicines Luis Brito, Ph.D., Vice President, Delivery Platform, Beam Therapeutics, USA	Big Molecules and Small Particles Lennart Lindfors, Ph.D., Senior Principal Scientist, Pharmaceutical Sciences, Pharmaceutical R&D, AstraZeneca, Sweden	Atom Economy and Sustainable Strategies in SPPS Walter Cabri, Ph.D., Full Professor of Organic Chemistry, University of Bologna, Italy

11:45	Transition to Spotlight Presentations		
11:50	Oligonucleotides & Chromatography – What's New? Patrick Endres, Manager, Product Management EMEA, Tosoh Bioscience GmbH, Germany 	BROTHERS: A Proprietary Antisense Oligonucleotide Platform for the Treatment of a Broader range of Diseases Tsuyoshi Yamamoto, Ph.D., CSO, Liid Pharmaceuticals and Associate Professor, Nagasaki University 	Spotlight Presentation 
12:20	Networking Luncheon in Poster and Exhibit Hall		
13:25	Enzymatic Oligonucleotide Manufacturing Combination with Solution Based Approach AJIPHASE® for Large Scale Daisuke Takahashi Ph.D., Executive Specialist, Ajinomoto Co. Inc., Japan 	Leveraging NMR Spectroscopy for High-resolution Structure Characterization of TIDES Victor Beaumont, Ph.D., Strategic Market Development Specialist, Bruker UK Limited 	Spotlight Presentation 
	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Targeted Delivery of Oligonucleotides and Preclinical Progress	Advances in Oligonucleotide Manufacturing	Innovations in Peptide Discovery, Design and Peptide CMC
13:55	Chairman's Remarks Jim Weterings, Ph.D., Vice President Research, RNA Therapeutics & Delivery, Sirnaomics, USA	Chairman's Remarks	Chairman's Remarks

Agenda | Thursday 14, November 2024

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Targeted Delivery of Oligonucleotides and Preclinical Progress	Advances in Oligonucleotide Manufacturing	Innovations in Peptide Discovery, Design and Peptide CMC
14:00	Novel TRiM™ Platform for Oligonucleotide Delivery to Trabecular Meshwork via Local Intracameral Administration Jing Chen, Ph.D., Director of Discovery DMPK, Arrowhead Pharmaceuticals, USA	Nitto CMC Presentation Nitto Avecia Speaker TBA	An Update on EMA Regulatory Guidelines for Peptides René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical Biotechnology, BfArM, Federal Institute for Drugs and Medical Devices, Germany (Invited)
14:30	Design and Application of Novel Peptide Conjugates for the Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cells Laurent Knerr, Ph.D., Principal Scientist, AstraZeneca, Sweden	Manufacturing of Long Oligos for Gene Editing, From HTP to GMP Fred Briones, Ph.D., Director, Oligonucleotide Chemistry, Tessera Therapeutics, USA	Pharmaceutical Industry Feedback and Reflections on EMA Draft Guideline for Development and Manufacture of Synthetic Peptides Osama Chahrour, Ph.D., Principal Scientist, Chemical Development, AstraZeneca, United Kingdom
15:00	GlycoConnect Antibody-oligonucleotide Conjugates for Targeted Treatment of Neuromuscular Diseases Floris van Delft, Ph.D., Head of R&D, SynAffix/Lonza, The Netherlands	Charting New Horizons in guide RNA Manufacturing Thi Lan Phuong Pham, Project Lead GMP and Large Scale Production, BioSpring GmbH	Peptide Synthesis Strategies for Production of Commercial GLP-1 Vera D'Aloisio, Ph.D., Sales Manager Europe, AmbioPharm, United Kingdom
15:30	Networking Refreshment Break in Poster and Exhibit Hall		
16:00	GalAhead™ muRNA: A Proprietary GalNAc-RNAi Therapeutic Platform for Simultaneous Downregulation of Multiple Genes Jim Weterings, Ph.D., Vice President Research USA, RNA Therapeutics & Delivery, Sirnaomics, USA	Challenges of Generic Oligonucleotide Drug Substance Development Michael Tikhonov, Analytical Group Manager, Oligonucleotides and Peptides, Teva, Israel Daniel Pinchuk, Ph.D., Oligonucleotide Team Leader, Chemical R&D, Teva, Israel	Opportunities and Challenges in the Large-Scale Manufacturing of Peptide APIs Jyothi Thundimadathil, Ph.D., Director of Drug Substance Development CMC, Carmot Therapeutics, USA

Agenda | Thursday 14, November 2024

	Oligonucleotide Discovery, Preclinical and Clinical	Oligonucleotide Chemistry, Manufacturing & Controls	Peptide Discovery to CMC
	Targeted Delivery of Oligonucleotides and Preclinical Progress	Advances in Oligonucleotide Manufacturing	Innovations in Peptide Discovery, Design and Peptide CMC
16:30	Delivery of Therapeutic RNAs into the Brain Ekkehard Leberer, Ph.D., Professor of Biochemistry and CEO, ELBIOCON, Germany	Oligonucleotide Solution API: Navigating the Regulatory Landscape Chris Chorley, Associate Director, Regulatory Affairs CMC, Biogen	Safety-Catch Solid-Phase Resins for Peptide Cleavage in the Absence of Acids Fernando Albericio, Ph.D., Research Professor, School of Chemistry, University of Kwazulu-Natal, South Africa
17:00	Delivery of Therapeutic siRNAs to Skin and Muscle Using Hydrophobic Conjugates Julia Alterman, Ph.D., Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Chan Medical School, USA	Late Breaking Presentation	Late Breaking Presentation
17:30	Close of Conference		

Meet The People Behind The Products & Get The Answers You Need

PLATINUM SPONSORS



GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS



Exhibitors

ADS Biotec	Hongene Biotech Corp	Scharlab
Almac Group	Inabata	ScinoPharm
Aspen Oss BV	Jiuzhou Pharma	Senn Chemicals
Asymchem	K&A Labs GmbH	Shenzhen Readline Technology
Aurisco	Kinovate Life Sciences	Sinopeg
BCN Peptides	Metabion International	Sousekai
Bio-Works	Milestone	Syncrest
BioPharmaSpec	Mitsui	Synoligo
Biosolve	Nankai Hecheng	Tosoh Bioscience
ChemGenes	Neuland Labs	TriLink Technologies
CPC Scientific	Nippon Shokubai	UFAG Laboratorien
CSBio	OPTIMA packaging group GmbH	U-genes
Dottikon Exclusive Synthesis	Orilife Biopharma	Vapourtec
Euroapi	PeptiSystems	W.L.Gore
Eurogentec	Phenomenex	Wuhu Huaren Science & Technology
Glen Research	Pukang Biotechnology	Yamasa
Glycogene	Quality Assistance	YMC ChromaCon
Gyros Protein Technologies	RiboBay	Ypso-Facto
Hanbon Science & Technology	RiboBio	ZY Biochemical Technology
Hera BioLabs	RIBOPRO	
	Sapala	

For more information on how you can connect with key buyers at TIDES Europe, contact:

#A-F: Jennifer Wickett, Phone: +1 (212) 600-3452

E-mail: Jennifer.Wickett@informa.com

G-Z: Michael Moriarty, +1 (646) 895-7412

E-mail: michael.moriarty@informa.com

2024 Pass Benefit Comparison

What's included in your pass

	Main Conference	Main Conference & Workshop Pass	Digital Experience Pass
All live in-person scientific presentations from world-renowned speakers	✓	✓	✗
60+ live booths in the exhibit hall	✓	✓	✗
Live poster presentations in poster hall	✓	✓	✗
Daily networking lunches and refreshment breaks	✓	✓	✗
All in-person live pre-conference workshops held	✗	✓	✗
1 year on-demand access to all approved main conference sessions	✓	✓	✗
Digital networking opportunities throughout the event	✓	✓	✓
All approved recordings of presentations from the in-person event	✓	✓	✓
Virtual exhibit and poster hall which consists of majority of vendors and poster presenters from live event	✓	✓	✓
The full attendee list (both live and digital only attendees) with capability to video chat, instant message and request meetings	✓	✓	✓

2024 Registration and Attendance Information

IN-PERSON PASS	SAVE £800 Register by 23 August, 2024	
Industry Rates	DISCOUNT	STANDARD RATE
Main Conference + Pre-conference Workshop	£2,899	£3,699
Main Conference Only	£2,499	£3,299
Academic/Govt Rates*		
Main Conference + Pre-conference Workshop	£1,499	£1,599
All Access Conference Pass	£1,099	£1,199

*Academic/Government rates are only extended to full-time employees of government, universities and university-affiliated hospitals with no industry affiliation.

DIGITAL PASS	SAVE £600 Register by 23 August, 2024	
Industry Rates	DISCOUNT	STANDARD RATE
Main Conference + Pre-conference Workshop	£2,499	£3,099
Main Conference Only	£2,099	£2,699
Academic/Govt Rates*		
Main Conference + Pre-conference Workshop	£1,399	£1,499
All Access Conference Pass	£999	£1,099

*Academic/Government rates are only extended to full-time employees of government, universities and university-affiliated hospitals with no industry affiliation.

[View Registration Options](#)

Poster Presentations

Share your company's scientific research by presenting a poster at TIDES Europe 2024. Be sure to sign up for a poster space when you register. Visit our [poster page](#) to learn more.

Venue

CCH - Congress Center Hamburg
Congresspl. 1, 20355 Hamburg, Germany
Phone: +49 40 35690

Group Discounts:

Register a group of 3+ to receive additional savings.

To register your group, please contact:

Tayla Thomas
Tayla.Thomas@informa.com
+44 (0) 20 8052 1571

Also Consider Attending

TIDES Asia 2024

26-28 Feb, 2025
Westin Miyako Kyoto
Kyoto, Japan

TIDES USA 2025

May 19-22, 2025
Manchester Grand Hyatt San Diego
San Diego, CA

3 WAYS TO REGISTER



ONLINE:
TIDSEuropeEvent.com



CALL
+44 (0) 20 8052 1571



EMAIL
register@informa.com